A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children

Hum Vaccin Immunother. 2014;10(7):1841-9. doi: 10.4161/hv.29008.

Abstract

This study aimed to calculate the cost-effectiveness of infant pneumococcal vaccination in the Netherlands, using the 13-valent PCV13 vs. the currently used 10-valent PCV10. We adapted a previously published model, using recent estimates of epidemiological and efficacy data. In 12 scenarios, we explored the impact of different assumptions on the incremental cost-effectiveness ratio (ICER) of PCV13 over PCV10.Taking only direct effects on invasive pneumococcal disease into account, PCV13 was not found to be cost-effective at a price difference of €11 per dose. If herd protection, replacement and non-invasive disease were also taken into account, the ICER of PCV13 compared with PCV10 was below €30 000/QALY gained in 11 of 12 scenarios. PCV13 was considered dominant in the primary scenario with a price difference below €2.63 per dose.

Keywords: Netherlands; PCV; Pneumococcal; cost-effectiveness; infant vaccination; vaccines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child, Preschool
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Netherlands / epidemiology
  • Pneumococcal Infections / economics
  • Pneumococcal Infections / epidemiology*
  • Pneumococcal Infections / prevention & control*
  • Pneumococcal Vaccines / administration & dosage*
  • Pneumococcal Vaccines / economics
  • Pneumococcal Vaccines / immunology*
  • Vaccination / economics*
  • Vaccination / methods

Substances

  • 10-valent pneumococcal vaccine
  • 13-valent pneumococcal vaccine
  • Pneumococcal Vaccines